Therapeutic Response

v::ALK status confers therapeutic sensitivity to Crizotinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Xalkori (crizotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized crizotinib for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Xalkori (crizotinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized crizotinib for the treatment of adult patients with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Crizotinib Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved crizotinib for reimbursement as a treatment option for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer, and whose ALK rearrangement has been demonstrated by an accurate and validate test method.
Xalkori (crizotinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to crizotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive, as detected by an FDA-approved test.